Rheumnow Podcast

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #4 ILD QD Clinics - Worsening Breathlessness in SSc ILD: The Pressure Is On ILD QD clinics on ILD #1 - Be Careful What you Look For

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 4: Rheum + Pulm Collaborations in ILD including The Rheumatologist and Pulmonologist: Different approaches to the same patient (Dr. Paul Dellaripa and Dr Rachel Putman).

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 3: ILD Assessment and Management including: Biomarkers in ILD (Dr. Elena Joerns), How to Assess ILD in Patients (Dr. Janet Pope) and Management of SSc ILD (Dr. Alicia Hinze)

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 2: ILD Treatment including: RA-ILD Treatment Update (Dr. Bryant England), Do DMARDS Affect CTD-ILD Outcomes? (Dr. Elizabeth Volkmann), Non-pharmacologic Treatment of ILD (Dr. Jon Giles) and Transplantation: A real option! (Dr. John Joerns)

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 1: ILD Guidelines including: ACR/CHEST Guidelines for SSc ILD (Dr. Sindhu Johnson), ERS/EULAR Clinical Practice Guidelines (Dr. Anna-Maria Hoffman-Vold) and ILD Guideline Caveats and Concerns (Dr. Jeffrey Sparks).

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Pool therapy, Fibrosis, NSIE's and whats best for knee OA.

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign ILD QD Clinic #3 ILD QD Clinic: Application of the ACR CHEST Guidelines to Two Cases ILD QD Clinic: Progressive RA-ILD Management ILD QD Clinic: Beyond the Numbers in Newly Diagnosed ILD

In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study: Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. doi: 10.1056 Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, Maher T.M., et al. Lancet 2023 Jan;11(1). doi: 10.1016 Panelists: Toby Maher, MD Shervin Assassi, MD Jack Cush, Moderator

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES: 1. SMILE Study: A randomized, placebo-controlled trial of hydroxychloroquine in incomplete lupus https://t.co/NnrA8ohiGX 2. Equal Safety of JAK Inhibitors and TNF Inhibitors in H2H IMID trials JAMA systematic review. https://t.co/HI1KBKZiXR 3. SMART study - Single vs. Split Dose Methotrexate https://t.co/lizsrtVHwf 4. Vegan diets don’t work in RA - Metanalysis of 7 studies https://t.co/jeh6gN5Byg 5. No association between IL-17 inhibitors & MACEs (vs TNFi Rx) https://t.co/fJuPFYKnSr https://t.co/Vscnsq0DTA 6. Successful Phase 3 UP-AA Trial evaluating Upadacitinib in Alopecia Areata (AA) https://t.co/8p1FvJx0s0 7. Anifrolumab effective & safe in refractory Cutaneous LE - OL Study in 15 CLE https://t.co/umEYz0XDyt 8. "Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has." - Margaret Mead https://t.co/OFGN223bPa

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs wont do & an FDA Pink Slip.

This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: Jeffrey Sparks, MD, Janet Pope, MD, Elena Joerns, MD Jack Cush, MD - Moderator

Dr. Peter Nash, Australia, reports highlights from a range of sessions presented at the APLAR 2025 Congress in Fukuoka, Japan. Hot Topics in AxSpA Precision Medicine in PsA PSA Therapeutic Update CAR T Therapy with Immunomediated Diseases Imaging Use of Micro CT Low Radiation for PsA

"QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign. Here are the individual video titles and links: ILD QD Clinic: Stick or twist (when not to change treatment) https://youtu.be/sdGPsvcfyzQ ILD QD Clinic: Interstitial Lung Disease with Positive SSA and Rash https://youtu.be/1H10_VR8t_0 ILD QD Clinic Video: RA and Bronchiectasis https://youtu.be/-StSi3v8ew8

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are their benefits to Diet/vegan diets? Whats the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.

Rheum to Breathe “ILD and Autoimmune Disease”: RA ILD Complications (Scott Matson): https://youtu.be/xTLvKLwlF-E ILD and Mortality (Bryant England): https://youtu.be/Ew9OW2o43Bg ILD in Sjorgen's (Nancy Cateron):https://youtu.be/BLVF2qvoR7E Truth of Fake: Idiopathic Interstitial Pneumonia with Autoimmune Features (Janet Pope): https://youtu.be/4Jk7nVeLIR8

This webinar will review the ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care. Panelists: Sindhu Johnson, MD Shane Shapera, MD Scott Matson, MD Jack Cush, MD - Moderator https://youtube.com/live/Viexwyv0sxs?feature=share

"QD clinics on ILD #1 - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign

Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogrens and alot of ILD.

Join panelists as they discuss rheumatologist impressions, knowledge and practices over the last 20 years when treating rheumatoid arthritis. Experts will unpack the results of a nationwide, three-part survey — covering treatment milestones, changing practices, and what the future holds for RA therapy. Don't miss this opportunity to hear what your peers are saying — and where the field is headed. Panelists: Katherine Liao, MD, MPH Stanley B. Cohen, MD Jeff Curtis, MD, MS, MPH Jack Cush, MD - moderator Sponsored by: Bristol Myers Squibb

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. Features Dr. Jack Cush, Editor at RheumNow.com.

Dr. Jack Cush reviews the news, journal reports, FDA approvals, drug safety, etc.

Dr. Jack Cush reviews the news, journal reports and press clippings from the past week on RheumNow. Positive results in a Sjogrens trial, to PT or not to PT, and aphorisms to live by.

Dr. Jack Cush reviews the news, reports, pipeline and drug repurposing on this weeks podcast.

Rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice. Sponsored by AstraZeneca Medical Affairs

Dr. Jack Cush reviews the news, journal reports and a new treatment for RA from the FDA.

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com Interesting case questions from "Ask Cush Anything"

Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Join rheumatology experts Dr. John J. Cush and Dr. Arthur Kavanaugh for the EULAR Rheumatology RoundUp — a dynamic, fast-paced discussion capturing the most impactful highlights, late-breaking data, and clinical takeaways from EULAR 2025.

Trends and Innovations from Barcelona (6.20.2025) AI Advances axSpA Diagnosis with Multimodal MRI IL-17 Inhibitors in Psoriatic Arthritis IL-17 Inhibitors for Axial Spondyloarthritis New IL-17 Inhibition New Molecular Constructs

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life Spondyloarthritis Panel: Eular 2025

Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.

Digital Behavioural Therapy for Persistent Pain in Axial Spondyloarthritis There's an App for That (and it works): the AXIA RCT

Eular 2025 PsA Topic Panel Assessment of Peripheral Arthritis in Spondyloarthritis IL-17 inhibitors - Novel Drugs IL17 inhibitors - Long-term Extensions and Uveitis IL17 inhibitors - STAMP T2T and Combinations Using AI for Reading PET/CT in Rheumatoid Arthritis

Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care.

Efficacy and Safety of Xeligekimab in AS Sonelokimab in PsA Seronegative Arthritis Breakthroughs Novel Therapies in Axial Spondyloarthritis

JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

Who/When to Treat Clinically Suspect Arthralgia Thoughtful, Effective RA Care Should be Guided by Need —Not Age The Impact of Biologics on Methotrexate Adherence Jokes Aside: The Impact of Laughter in RA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

Efficacy and Safety of Xeligekimab in AS Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis GLP 1 Receptor Agonists in axSpA Patients

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact

EULAR 2025 - Day 1 podcasts Sonelokimab in PsA Seronegative Arthritis Breakthroughs Using Combination csDMARDs in PsA Deucravacitinib's Place in the PsA Treatment Algorithm?

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor Agonists in axSpA Patients Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

Difficult to Treat Psoriatic Arthritis Less or more frequent dosing in PsA? Complex-to-Manage PsA: The GRAPPA Framework and Definition Emerging Therapies in Axial Spondyloarthritis Chronic Pain in AxSpA Beyond Fibromyalgia Novel Therapies in Axial Spondyloarthritis JAK Inhibitors: The Latest from the JAK-pot Study Does Abatacept Buy You Time Off RA? How to Properly Use Steroids in Early RA: Oral vs Parenteral All Rheumatoid Arthritis is Not the Same

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the fourth day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.

Deucravacitinib's Place in the PsA Treatment Algorithm? Lessons on Uveitis and AxSpA Difficult to Treat Axial Spondyloarthritis MRI Lesions in Early axSpA vs Non-axSpA JAK Safety Update Why is RA Difficult to Treat? DMARD Combinations in RA Treatment Increased Risk of VTE in RA: Lessons Learned from 40 Years of Data ALTO: Long-term Outcomes of APIPPRA

Catch up on the biggest breakthroughs, standout sessions, and expert insights from the third day of EULAR 2025. Join us live as we break down the key highlights and what they mean for the future of rheumatology.